Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06WYG
|
||||
| Former ID |
DIB000119
|
||||
| Drug Name |
99mTc-MIP-1407
|
||||
| Synonyms |
MIP-1407; MIP-1407-[99mTc]; Somatostatin receptor modulator imaging agent (neuroendocrine cancer), Molecular Insight; Technetium-99m-MIP-1407
|
||||
| Indication | Neuroendocrine cancer [ICD10:C7A] | Investigative | [543791] | ||
| Company |
Molecular Insight Pharmaceuticals Inc
|
||||
| Canonical SMILES |
c1cnc(n1CN(CCCC[C@H](N)C(=O)N[C@@H](C(=O)N[C@@H]1C(=O)N<br />[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](<br />C(=O)N[C@@H]([C@H](O)C)CO)CSSC1)[C@H](O)C)CCCCN)Cc1c[nH<br />]c2c1cccc2)Cc1ccc(cc1)O)Cc1ccccc1)Cn1ccnc1CC(=O)O)CC(=O<br />)O.[99Tc].[C-]#[O+].[C-]#[O+].[C-]#[O+]
|
||||
| Target and Pathway | |||||
| Target(s) | Somatostatin receptor 1 | Target Info | Modulator | [530618], [532210] | |
| Somatostatin receptor type 3 | Target Info | Modulator | [530618], [532210] | ||
| Somatostatin receptor type 2 | Target Info | Modulator | [543788] | ||
| Somatostatin receptor type 4 | Target Info | Modulator | [543790] | ||
| Somatostatin receptor type 5 | Target Info | Modulator | [543791] | ||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| PathWhiz Pathway | Gastric Acid Production | ||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like | |||||
| GPCR downstream signalingWP706:SIDS Susceptibility Pathways | |||||
| GPCR downstream signaling | |||||
| GPCRs, OtherWP455:GPCRs, Class A Rhodopsin-like | |||||
| References | |||||
| Ref 530618 | Mol Endocrinol. 2010 Feb;24(2):436-46. Epub 2010 Jan 5.Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation. | ||||
| Ref 532210 | Nat Rev Drug Discov. 2013 Feb;12(2):87-90. | ||||
| Ref 543788 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 356). | ||||
| Ref 543790 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 358). | ||||
| Ref 543791 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 359). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.